Taysha Gene Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	14.16	15.45	2.5	0	0
Revenue Growth (YoY)	96.39%	517.55%	-	-	-
Gross Profit	14.16	15.45	2.5	0	0
Selling, General & Admin	28.38	30.05	37.36	41.32	11.11
Research & Development	64.92	56.78	91.17	131.94	31.89
Other Operating Expenses	1.07	1.07	36.42	0	0
Operating Expenses	94.37	87.89	164.95	173.27	43
Operating Income	-80.21	-72.44	-162.45	-173.27	-43
Interest Expense / Income	3.65	5	3.8	1.43	0.03
Other Expense / Income	34.14	34.13	-0.23	-0.17	16.98
Pretax Income	-118.01	-111.57	-166.01	-174.52	-60.01
Net Income	-118.01	-111.57	-166.01	-174.52	-60.01
Shares Outstanding (Basic)	231	116	44	38	18
Shares Outstanding (Diluted)	231	116	44	38	18
Shares Change	265.55%	164.20%	16.74%	113.13%	-
EPS (Basic)	-0.49	-0.96	-3.78	-4.64	-3.40
EPS (Diluted)	-0.49	-0.96	-3.78	-4.64	-3.40
Free Cash Flow	-72.74	-76.89	-109.01	-132.35	-30.81
Free Cash Flow Per Share	-0.32	-0.66	-2.48	-3.52	-1.74
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	-566.61%	-468.83%	-6492.69%	-	-
Profit Margin	-833.60%	-722.06%	-6635.25%	-	-
Free Cash Flow Margin	-513.85%	-497.62%	-4356.87%	-	-
EBITDA	-111.78	-104.02	-159.73	-172.6	-59.97
EBITDA Margin	-789.63%	-673.19%	-6384.05%	-	-
Depreciation & Amortization	2.57	2.55	2.49	0.49	0.01
EBIT	-114.35	-106.57	-162.22	-173.1	-59.98
EBIT Margin	-807.80%	-689.72%	-6483.45%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).